CRL logo

CHARLES RIVER LABORATORIES

CRLNYSE
πŸ† #703 by market capUS Equity
$296.11β–² $1.57 (+0.53%)
After hours Β· at close
πŸ””
Track CRL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.5%
7dβ–² 3.9%
14dβ–² 8.6%
30dβ–² 1.5%
ytdβ–² 48.3%
1yβ–² 101.6%
🏦Market Cap
$14.26B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-0.8%
Declining
πŸ“ŠGross Margin
32.2%
Moderate
πŸ’΅FCF Margin
9.3%
Moderate
βš–οΈP/S Ratio
3.5x
Fair
Otter Score
76
Good

Trading Snapshot

Day Range
$294.20 – $301.70
52-Week Range
$145.47 – $303.31
Volume
$2.15B
Avg Volume
$1.61B
Shares Outstanding
48.2M
Next Earnings
Oct 22, 2026

Fundamentals Snapshot

Annual Revenue
$4.00B
Last Q Revenue
$1.09B
P/E Ratio
-60.5
P/S Ratio
3.5x
EPS (TTM)
$-4.92
Dividend Yield
0.00%

Why Investors Own CRL

  • βœ“High-growth profile β€” revenue up +54.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 65% gross margin and 10% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CRL logo

CHARLES RIVER LABORATORIES

CRL
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$4.00Bβ–² +57.3% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.9%β–² +3.2% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$520Mβ–² +57.3% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$412Mβ–² +57.3% YoY
StockOtter Β· stockotter.space

About CHARLES RIVER LABORATORIES

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$395.63
β–² +33.6% Upside
High Target$451.70
Low Target$333.76
Based on 35 analysts

Latest News & Updates